The new service provides biopharmaceutical clients with a comprehensive way to measure the genetics of drug metabolism in clinical trial patients – giving drug developers the opportunity to select patients that are more likely to respond, said AltheaDx.
AltheaDx will provide its customers with a report featuring a patient’s genetic data in an interpretable format that can be directly integrated into existing protocols. This is made possible by leveraging software tools to translate raw genetic data from each patient into a conventional star allele nomenclature, with which biopharma project teams are familiar, noted AltheaDx.
The Drug Metabolizing Enzymes & Transporter (DMET) microarray service is an expansion of the AltheaDx offering, which includes all Affymetrix expression microarrays: 3′ IVT, Gene Array and Exon Arrays, along with SNP 6.0 genotyping arrays.
Tommy Broudy, director of sales for biomarkers at AltheaDx, said: “Our customers will have a single report, from a single test, to look at proven genetic variations and valid biomarkers that may be affecting drug metabolism of their compounds. Taking this comprehensive approach is critical, particularly when preclinical hypotheses about specific variations don’t prove out, and questions remain about potential dosing or drug response issues.”